List of Wound Healing Companies with Phase 2 Active Clinical Trial - 23

Amnio Technology is an industry leader in the development and manufacture of amnion-derived technologies. Amnio Technology manufactures high-quality, amnion-derived technologies for clinical use.

Applied Biologics is a fully-integrated life sciences company providing research, product development, manufacturing and distribution of medical technologies. Since 2010, Applied Biologics has been dedicated to providing innovative biologic solutions to deliver optimal patient outcomes. The entire Applied Biologics team is dedicated to each other and the company's success. The executive team, medical advisory board, scientific advisory board, researchers, product development team, manufacturing technicians, distribution team, sales representatives, support team, reimbursement department and administrative staff are professionals and leaders in their fields. Together, we continue to strive for excellence and being a leader in delivering biological solutions to treat a growing list of medical indications.

AVITA Medical (NASDAQ: RCEL, ASX:AVH) is a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration. At the forefront of our platform is the RECELL® System, approved by the U.S. Food and Drug Administration for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. RECELL harnesses the regenerative properties of a patient's own skin to create Spray-On Skin™ Cells, delivering a transformative solution at the point-of-care. This breakthrough technology serves as the catalyst for a new treatment paradigm enabling improved clinical outcomes. AVITA Medical also holds the exclusive rights to market, sell, and distribute PermeaDerm®, a Biosynthetic Wound Matrix, in the United States.

B. Braun is one of the world's leading medical technology companies. With over 65,000 employees, the family-owned company is a true partner, developing smart solutions and setting standards to drive advancements in health care. In 2022, the B. Braun Group generated sales of € 8.5 billion. You want to protect and improve the health of people around the world? Then you need a work environment that makes it easy for you to give your best. We bring together people in a collaborative culture. We encourage them to be open-minded, learn from each other and create new solutions together. In a time of rapid technological change, we constantly strive to enhance the solutions we provide. This is why we promote innovative ways of thinking and accountability. Imprint: https://www.bbraun.com/en/imprint.html Privacy Policy: https://www.bbraun.com/en/privacy-policy.html

Developing new drugs under FDA regulation for hypoxia brain and heart ischemia and viral infection like coronavirus and influenza.

BPGbio is a clinical-stage biopharma reimagining how patient biology can be modeled using unbiased AI algorithms, to accelerate and de-risk the process of drug discovery for humanity. Our Interrogative Biology® platform has produced and guided development of more than a dozen therapeutics and diagnostics candidates in the areas of oncology, neurology and rare diseases, including several in advanced clinical stages. As BPGbio continues to expand our biobank, and the network insights that are derived from it, we anticipate more promising discoveries made with improved time and cost efficiency.

BRIM is a clinical-stage company developing novel peptide treatments for hard-to-treat diseases. BRIM’s first-in-class assets are based on its innovative stem cell regenerative PDSP technology platform, which has the potential to be effective in multiple therapy areas and indications.

Clene Inc., a clinical-stage biopharmaceutical company, focuses on the development of various therapeutics for neurodegenerative diseases. The company has a nanotechnology drug platform for the development of orally administered neurotherapeutic drugs. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2 study for the treatment of stable multiple sclerosis; a Phase 2 biomarker study in Parkinson’s; and Phase 2 and Phase 3 trials to investigate the potential for disease modification for neurodegenerative diseases. The company’s products also include CNM-AgZn17, a topical gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; and NM-PtAu7, a gold-platinum CSN therapeutic. Clene Inc. is based in Salt Lake City, Utah.

At Convatec, #ForeverCaring is our promise to patients & healthcare providers, as we deliver pioneering trusted medical solutions to improve the lives we touch. #ForeverConvatec

At Elutia we’re pioneering the future of patient care. Our proprietary drug-eluting biomaterial platforms stand at the forefront of medical innovation.

Embody, Inc. is a commercial-stage company pioneering the next generation in collagen-based tendon and ligament healing for the fast-growing sports medicine market. Founded in 2014, the company is developing unique biomaterials with an initial focus on orthopedic applications including Achilles, rotator cuff and knee ligament repair.

Femasys is a biomedical company focused on transforming women's healthcare worldwide by developing novel solutions and next-generation advancements providing significant clinical impact to address severely underserved areas. With an initial focus in the area of reproductive health, its two lead product candidates offer solutions to improve patient care and health economics: FemBloc®, a first and only non-surgical product for permanent birth control and FemaSeed™, a first and only directed sperm delivery product for infertility treatment. Femasys' FemVue® product for fallopian tube assessment by ultrasound is currently marketed in the United States as its main commercial priority. Femasys has also developed a novel technology platform for tissue sampling intended to be marketed alongside our other women-specific medical products in the physician's office setting.

Weaving along Hawaii's Na Pali Coast is the famous, breathtaking Kalalau trail. This trail is not only notable for its strenuous path and terrain that is difficult to traverse, but also known for its unsurpassed beauty. Kalalau was early inspiration for us, today representing our innovative spirit and deep commitment to advancing the treatment of eye diseases. KALA BIO is a clinical-stage biopharmaceutical company dedicated to the research and development of innovative therapies for rare and severe diseases of the eye. KALA BIO’s biologics-based investigational therapies utilize KALA BIO’s proprietary mesenchymal stem cell secretome (MSC-S) platform. KALA BIO’s lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. KPI-012 is currently in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing, for which it has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration. KALA BIO is also targeting the potential development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases that threaten vision and has initiated preclinical studies to evaluate the potential utility of its MSC-S platform for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease. For more information on KALA BIO, please visit www.kalarx.com.

With 81 patents and patents pending, Kane Biotech is Kane Biotech is THE Biofilm Company. Creating smarter ways to fight bacteria, Kane is leading the advancement of technologies and products that break up biofilms and destroy bacteria. Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. StrixNB™, DispersinB®, Aledex™, bluestem™, bluestem®, silkstem™, goldstem™, coactiv+™, coactiv+®, DermaKB™ and DermaKB Biofilm™ are trademarks of Kane Biotech Inc. The Company is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol "KNBIF".

KiOmed Pharma is a biotechnology company based in Belgium that focuses on developing, manufacturing, and distributing chitosan-based medical devices. The company, a spinout from KitoZyme, utilizes exclusive natural chitosan chemistry to create solutions for high-impact medical conditions, particularly in osteoarthritis, dermatology, and ophthalmology. Headquartered in Herstal, Liège, KiOmed Pharma emphasizes therapeutic innovations through its proprietary KiOmedine® technology platform. One of its key products is KioMedine(vs)one, a single-injection soft implant designed to relieve pain and improve mobility in knee osteoarthritis patients. The company is also developing additional products targeting joint health, skin aging, and eye-related disorders. KiOmed Pharma maintains a commitment to biocompatibility and safety by using non-animal-derived chitosan in its formulations. In April 2024, KiOmed Pharma formed a strategic alliance with Aptissen to globally commercialize KioMedine(vs)one, enhancing patient access to its treatments while generating revenue through royalties and milestone payments. Under the leadership of CEO Houtaï Choumane, the company aims to create long-term value and improve patient outcomes in chronic diseases.

MolecuLight Inc. a privately-owned medical imaging company that has developed and is commercializing its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight’s suite of commercially released devices, including the MolecuLight i:X® and DX™ fluorescence imaging systems and their accessories, provide point-of-care handheld imaging devices for the global wound care market for the real-time detection of wounds containing elevated bacterial burden > 10^4 CFU/g (when used with clinical signs and symptoms) and for digital wound measurement #moleculight

Primex ehf is an icelandic marine biotech company who is a global leader in the manufacture and supply of chitosans and chitin derivatives. The traceability of ChitoClear TM starts by registering the catching area of the shrimp in the North Atlantic Ocean.

Progenitec is a healthcare company that facilitates faster healing of chronic wounds through accurate and fast diagnosis.

A forward-thinking, medical technology company dedicated to developing life-saving products and therapies that encourage healing, reduce complications of tissue damage and inflammation, prevent infection by drug-resistant bacteria and remove the biofilms in which they thrive. We use the best of nature to solve important, real-time problems.

Telios Pharma, Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California, specializing in developing therapies for mast cell-mediated inflammatory diseases. Founded in 1993, the company focuses on small-molecule drugs and has a team of 51 to 100 employees. Its annual revenue is estimated between $10 million and $25 million. The company's pipeline includes innovative Bruton’s tyrosine kinase (BTK) inhibitors. Notable candidates are TL-925, a topical eye drop for dry eye disease currently in Phase 2 trials, and M-7583, an oral BTK inhibitor for primary myelofibrosis. TL-925 has shown promising results, providing rapid relief from symptoms and significant improvements in clinical measures. Telios Pharma aims to address significant unmet needs in both dry eye disease and myelofibrosis, targeting markets with limited existing therapies.

Theravia is an international pharmaceutical laboratory based in France, focusing on rare, neglected, and debilitating diseases. Formed from the merger of Addmedica and CTRS, the company operates in over 35 countries across five continents. Theravia is dedicated to addressing unmet medical needs through innovative therapies and strategic partnerships. The company develops, registers, and promotes specialized medical products, including pharmaceuticals, medical devices, and diagnostics. Their portfolio features six registered products, such as Siklos for sickle cell disease and Orphacol for genetic disorders affecting bile acid production. Theravia collaborates with research groups and healthcare institutions to enhance disease awareness and improve treatment accessibility for over 15,000 patients globally. With more than 20 years of experience in rare disease therapeutics, Theravia emphasizes patient-centric solutions and adaptive strategies. The company has established over 30 partnerships worldwide, reflecting its commitment to advancing healthcare for those with rare metabolic, hematologic, and immunologic conditions.

Vomaris Innovations, Inc. is a medical device company based in Tempe, Arizona, that focuses on bioelectric technology for infection control and wound healing. Founded in 2004, the company operates globally, with its products registered in nine countries and over one million wounds treated using its technology. The company's patented V.Dox™ Technology utilizes moisture-activated microcell batteries embedded in a substrate. This technology generates a wireless electric field that mimics the body's natural healing process, targeting bacterial biofilms and reducing infection risk. Vomaris offers products such as the Procellera® Antimicrobial Wound Dressing, which is validated in numerous peer-reviewed publications, and the PowerHeal™ Antibacterial Bioelectric Bandages, available over-the-counter for superficial wounds. Their solutions are applicable in various medical fields, including chronic and acute wound care, surgical incisions, and veterinary medicine.

Xinnate is a young biopharmaceutical company built on groundbreaking scientific research about innate defence and healing mechanisms – evolutionary biological systems with the purpose of keeping us healthy. One of these innate defence peptides has shown to be an effective ”natural” and unique way of preventing infection as well as reducing excessive inflammation. Xinnate specializes in the development of proprietary peptide-based drugs for prevention and treatment of inflammatory diseases and infections within the areas skin and wounds, surgical materials and and biomaterials. The company was founded in 2019 and is based on 15 years of world class research from Lund University. The first area to be addressed by Xinnate is advanced wound care, and the first product is a hydrogel, the BioC wound gel, aimed for treatment of burn wounds.